Mirion’s second quarter results were met with a negative market reaction, as revenue came in below Wall Street expectations despite a nearly 20% year-over-year increase. Management attributed the revenue outcome to mixed performance across its segments, with growth in nuclear power offset by declines in new build projects and delayed hardware demand in the medical segment. CEO Thomas D. Logan pointed to “expanding adjusted EBITDA margins from both operating segments and across the total enterprise,” highlighting the positive impact of product mix and pricing. The company also faced an unexpected contract cancellation in China, which management described as unusual but not indicative of broader risk to its backlog.
Is now the time to buy MIR? Find out in our full research report (it’s free for active Edge members).
Mirion (MIR) Q2 CY2026 Highlights:
- Revenue: $266.8 million vs analyst estimates of $269.6 million (19.7% year-on-year growth, 1% miss)
- Adjusted EPS: $0.12 vs analyst estimates of $0.10 (17% beat)
- Adjusted EBITDA: $65.3 million vs analyst estimates of $62.78 million (24.5% margin, 4% beat)
- Management reiterated its full-year Adjusted EPS guidance of $0.52 at the midpoint
- EBITDA guidance for the full year is $292.5 million at the midpoint, above analyst estimates of $289.5 million
- Operating Margin: 6.9%, up from 4.6% in the same quarter last year
- Market Capitalization: $3.81 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Mirion’s Q2 Earnings Call
- James West (Melius Research) asked about the probability of winning large pipeline opportunities. CEO Thomas D. Logan said Mirion sees a “right to win” on these prospects, with recent quarters showing strong conversion rates, but admitted timing remains the biggest risk to translating pipeline into revenue.
- Joseph Ritchie (Goldman Sachs) questioned the visibility behind the implied fourth-quarter growth in the nuclear and safety segment. CFO Brian Schopfer pointed to consistent backlog coverage and noted that easier year-over-year comparisons should support the ramp, but acknowledged the need for continued order wins and execution.
- Quinn Fredrickson (Baird) asked whether SMR revenue contribution could scale further in 2027, given recent order momentum. Logan responded that while cautious historically, current trends and positioning suggest SMR growth will likely outpace overall organic growth for the foreseeable future.
- Andrew Kaplowitz (Citigroup) brought up the apparent disconnect between robust order growth and flat nuclear power revenue in Q2. Schopfer clarified that revenue recognition lags order wins, and expects all three nuclear business areas—installed base, SMR, and new build—to contribute more meaningfully in the back half.
- Chris Moore (CJS Securities) pressed management on the achievability of long-term EBITDA margin targets in light of recent M&A. Logan reaffirmed the goal, citing operating leverage, procurement improvements, and internal productivity as the main levers for achieving higher margins, while acknowledging incremental AI investments.
Catalysts in Upcoming Quarters
In upcoming quarters, our analysts will be watching (1) the pace of conversion from robust nuclear and SMR order backlog into revenue, (2) evidence that medical hardware demand and software momentum are translating into sustained growth, and (3) the impact of AI-driven product launches and operational improvements on margin expansion. Additionally, we will monitor M&A activity, backlog quality, and the resolution of any outstanding contract issues.
Mirion currently trades at $15.69, down from $16.79 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
The Best Stocks for High-Quality Investors
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.